Alembic Secures Final USFDA Nod for Tretinoin Cream USP, 0.025%
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Tretinoin Cream USP, 0.025 percent, indicated for the treatment of acne vulgaris.
Generic Pharmaceuticals | 16/08/2025 | By Dineshwori | 349
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy